Long-term safety of tiotropium/olodaterol Respimat(®) in patients with moderate-to-very severe COPD and renal impairment in the TONADO(®) studies

INTRODUCTION: The safety, lung function efficacy, and symptomatic benefits of combined tiotropium and olodaterol in patients with COPD were established in the 1-year TONADO(®) studies (NCT01431274; NCT01431287). As tiotropium is predominantly excreted by the kidneys, the long-term safety profile of...

Descripción completa

Detalles Bibliográficos
Autores principales: LaForce, Craig, Derom, Eric, Bothner, Ulrich, Kloer, Isabel M, Trampisch, Matthias, Buhl, Roland
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5987861/
https://www.ncbi.nlm.nih.gov/pubmed/29910611
http://dx.doi.org/10.2147/COPD.S161489

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5987861/
https://www.ncbi.nlm.nih.gov/pubmed/29910611
http://dx.doi.org/10.2147/COPD.S161489

Ejemplares similares